Published in
American Association for the Advancement of Science, Science Translational Medicine, 609(13), 2021
DOI: 10.1126/scitranslmed.abb3312
Links
Tools
JUN promotes hypertrophic skin scarring via CD36 in preclinical in vitro and in vivo models
Journal article published in 2021 by
Michelle F. Griffin 
,
Mimi R. Borrelli ,
Julia T. Garcia,
Michael Januszyk,
Megan King,
Tristan Lerbs,
Lu Cui ,
Alessandra L. Moore ,
Abra H. Shen ,
Shamik Mascharak ,
Nestor M. Diaz Deleon,
Sandeep Adem,
Walter L. Taylor ,
Heather E. desJardins-Park ,
Marc Gastou
and other authors.
,
Mimi R. Borrelli ,
Julia T. Garcia,
Michael Januszyk,
Megan King,
Tristan Lerbs,
Lu Cui ,
Alessandra L. Moore ,
Abra H. Shen ,
Shamik Mascharak ,
Nestor M. Diaz Deleon,
Sandeep Adem,
Walter L. Taylor ,
Heather E. desJardins-Park ,
Marc Gastou
and other authors.
This paper was not found in any repository, but could be made available legally by the author.
Full text: Unavailable
Published version:
archiving forbidden
Data provided by 
Abstract
JUN drives scarring by modifying the roles of fibroblast subpopulations, and JUN antagonism via CD36 may represent an antiscarring therapy.